Human papillomavirus in cervical cancer.
Human papillomavirus in cervical cancer.
复制标题
DOI：
10.1007/s11912-002-0079-y
复制
发表时间：
2002-03-01
影响因子：
4.7
通讯作者：
de Sanjose, Silvia
中科院分区：
文献类型：
--
作者：
Bosch, F Xavier;de Sanjose, Silvia
分子技术支持的流行病学研究已经提供了足够的证据，证明某些人乳头瘤病毒（HPV）感染在宫颈癌发展中的因果作用。这一发现是普遍一致的，HPV被认为是第一个确定的宫颈癌的必要原因。这种认识转化为一个概念，即如果没有持续存在的HPV DNA，宫颈癌就不会发展。在世界发达地区，细胞学筛查项目可以受益于在其方案中增加HPV检测。对照研究和一项随机试验表明，HPV检测有助于解决细胞学检查产生的模棱两可的病例。在细胞学项目功能不强或效率不高的人群中，HPV检测正在被评估为初级筛查的替代方法。预防暴露于高危型人乳头瘤病毒，无论是通过预防性疫苗接种，还是通过预防性和治疗性免疫干预相结合，可能被证明是预防发展中人群宫颈癌的最有效和后勤上可行的选择。
Epidemiologic studies supported by molecular technology have provided sufficient evidence of the causal role of some human papillomavirus (HPV) infections in the development of cervical cancer. The finding is consistent universally, and HPV has been proposed as the first identified necessary cause of cervical cancer. Such recognition translates into the concept that cervical cancer does not develop without persistent presence of HPV DNA. In the developed parts of the world, cytologic screening programs could benefit from the addition of HPV testing to their protocols. Controlled studies and one randomized trial have shown that HPV testing is helpful in solving the ambiguous cases generated by cytology reading. In populations where cytology programs are not functional or efficient, HPV testing is being evaluated as an alternative means of primary screening. Prevention of exposure to high-risk HPV types, either by prophylactic vaccination or by combined prophylactic and therapeutic immunologic intervention, may prove to be the most efficient and logistically feasible option for the prevention of cervical cancer in developing populations.